X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Natco Pharma Fact Sheet, Natco Pharma Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Natco Pharma Fact Sheet   (NTPH)

Here is the latest financial fact sheet of Natco Pharma. For more details, see the Natco Pharma quarterly results and Natco Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

NATCO PHARMA Price History

Price Rs 522.4
Mkt Cap Rs m 86,788
Vol '000 6.3
P/E X 10.6
P/CF X 11.4
EPS (TTM) Rs 49.5
% ch % -0.4
No. of shares m 166.15
% ch week % -3.5
% ch 1-mth % -3.6
% ch 12-mth % -34.5
52 week H/L Rs 849.0/519.0
(As on May 17, 2019 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

NATCO PHARMA Financials

No. of Mths
Year Ending
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
5-Yr Chart
Click to enlarge
NATCO PHARMA EQUITY SHARE DATA
High Rs8772,2916248491,080 
Low Rs424656366418671 
Sales per share (Unadj.) Rs223.4248.4327.8578.9592.1 
Earnings per share (Unadj.) Rs31.137.643.5138.9188.4 
Diluted earnings per shareRs6.27.59.129.241.8 
Cash flow per share (Unadj.) Rs40.351.858.2154.5206.3 
Dividends per share (Unadj.) Rs5.005.001.256.758.25 
Adj. dividends per shareRs1.001.000.261.421.83 
Dividend yield (eoy) %0.80.30.31.10.9 
Book value per share (Unadj.) Rs219.5254.6372.8473.8833.6 
Adj. book value per shareRs43.750.978.199.5185.1 
Shares outstanding (eoy) m33.0733.2334.8334.9036.90 
Bonus/Rights/Conversions  PA-ISISIS 
Price / Sales ratio x2.95.91.51.11.5 
Avg P/E ratio x20.939.211.44.64.6 
P/CF ratio (eoy) x16.128.48.54.14.2 
Price / Book Value ratio x3.05.81.31.31.1 
Dividend payout %16.113.32.94.94.4 
Avg Mkt Cap Rs m21,50448,96317,23022,11632,311 
No. of employees `000NA3.11.34.44.8 
Total wages/salary Rs m1,1281,3691,8672,4323,256 
Avg. sales/employee Rs ThNM2,647.78,462.64,579.94,522.5 
Avg. wages/employee Rs ThNM439.31,383.8551.3674.0 
Avg. net profit/employee Rs ThNM400.81,124.21,099.31,439.0 
NATCO PHARMA INCOME DATA
Net Sales Rs m7,3898,25311,41620,20221,848 
Other income Rs m167149108139404 
Total revenues Rs m7,5568,40211,52420,34122,252 
Gross profit Rs m1,7932,1002,6406,8349,284 
Depreciation Rs m304473510544662 
Interest Rs m366317229185154 
Profit before tax Rs m1,2901,4592,0096,2448,872 
Minority Interest Rs m46-44-1400 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m0-151000 
Tax Rs m309154791,3951,920 
Profit after tax Rs m1,0271,2491,5174,8496,952 
Gross profit margin %24.325.423.133.842.5 
Effective tax rate %23.91.023.922.321.6 
Net profit margin %13.915.113.324.031.8 
NATCO PHARMA BALANCE SHEET DATA
Current assets Rs m3,6814,8308,32310,87321,307 
Current liabilities Rs m3,1234,1374,9296,2655,920 
Net working cap to sales %7.68.429.722.870.4 
Current ratio x1.21.21.71.73.6 
Inventory Days Days89971146373 
Debtors Days Days59858486107 
Net fixed assets Rs m7,6858,3899,25311,69314,986 
Share capital Rs m331332348349369 
"Free" reserves Rs m6,6707,94512,37316,14430,353 
Net worth Rs m7,2598,46112,98316,53430,760 
Long term debt Rs m955970000 
Total assets Rs m11,95713,84018,23823,17637,151 
Interest coverage x4.55.69.834.858.6 
Debt to equity ratio x0.10.1000 
Sales to assets ratio x0.60.60.60.90.6 
Return on assets %11.711.39.621.719.1 
Return on equity %14.214.811.729.322.6 
Return on capital %20.716.817.138.929.3 
Exports to sales %39.434.727.500 
Imports to sales %5.76.510.200 
Exports (fob) Rs m2,9082,8663,14100 
Imports (cif) Rs m4215381,16800 
Fx inflow Rs m3,4453,1563,4576,79310,322 
Fx outflow Rs m7039591,6882,2542,978 
Net fx Rs m2,7432,1971,7694,5387,343 
NATCO PHARMA CASH FLOW
From Operations Rs m 1,440 927 1,024 3,458 4,636 
From Investments Rs m -1,089 -1,148 -1,755 -2,994 -11,155 
From Financial Activity Rs m -353 291 856 -477 6,509 
Net Cashflow Rs m -1 22 117 -7 -18 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 52.0%
Foreign collaborators 1.5%
Indian inst/Mut Fund 7.8%
FIIs 16.6%
ADR/GDR 0.0%
Free float 26.0%
Shareholders 25,395
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF NATCO House, Road No.2, Banjara Hills, Hyderabad - 500 033
E-MAIL investors@natcopharma.co.in WEB www.natcopharma.co.in
TELEPHONE (040) 2354 7532 FAX (040) 2354 8243
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Venture Capital, 12-10-167, Bharatnagar, Hyderabad-500 018
AUDITOR Walker, Chandiok & Co.
CHM: V. C. Nannapaneni (MD) COMP SEC: M. Adinarayana YEAR OF INC: 1981 BSE CODE: 524816 FV (Rs): 10 DIV YIELD (%): 0.4

More Pharmaceuticals Company Fact Sheets:   GSK PHARMA  FDC LTD.  ASTRAZENECA PHARMA  MERCK  FRESENIUS KABI ONCO.  

Compare NATCO PHARMA With:   GSK PHARMA  FDC LTD.  ASTRAZENECA PHARMA  MERCK  FRESENIUS KABI ONCO.  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

US China Trade War Escalations and Election Results: Volatility Set to Rule(Podcast)

India could be the latest direct victim of the US-China trade war. The increasing escalations have already slowed down global growth.

Views on news

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

Limited Upside, Higher Downside(The Honest Truth)

May 6, 2019

The market's irrational reaction may present opportunities for a limited period of time.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NATCO PHARMA

NATCO PHARMA - DISHMAN PHARMA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS